Rochester, MN - A case report of a patient who suffered erosion of an Amplatzer septal-occluder device (St Jude Medical) six years after it was implanted, resulting in cardiac tamponade and ...

The notion of obliterating the LAA grew out of the knowledge that most of the systemic emboli leading to stroke in patients with AF originate from the LAA. LAA exclusion was first attempted surgically ...

The cardiologist determines what size Amplatzer occluder to use by inflating a small balloon within the defect, and measuring the indentation in the balloon created by the defect. The Amplatzer ...

First and only steerable delivery system designed to help seal the left atrial appendage (LAA) in people with atrial fibrillation who are at an increased risk of stroke Now available in the U.S., ...

TCT 195: Percutaneous Patent Foramen Ovale Closure for Migraine with the Amplatzer PFO Occluder: A Pooled Analysis of Individual Participant Data from the Randomized Trials Receive the the latest news ...

ABBOTT PARK, Ill., Aug. 30, 2021 /PRNewswire/ -- Abbott (NYSE: ABT) today announced late-breaking data from the Amulet™ LAA Occluder IDE trial, a multi-center, head-to-head study comparing the company ...

At 2-year follow-up, a septal occluder device was deemed safe and effective for transcatheter closure of atrial septal defects, according to new data published in Circulation: Cardiovascular ...

While rare, infective endocarditis is a devastating complication after device closure of atrial septal defects (ASDs), and much remains unknown about when infections begin and how clinicians can best ...

The AMPLATZER ™ Cardiac Plug Clinical Trial (ACP Trial) is designed to determine if the ACP device is safe and effective in preventing thrombus (blood clots) from migrating out of the left atrial ...

AbbottABT recently announced results for its AMPLATZER Amulet left atrial appendage (LAA) occlusion device in a bid to fortify its core Structural Heart business. Data was presented at EuroPCR, the ...